Picture of boy being examining by doctor at a tuberculosis sanatorium

Understanding our future through Open Access research about our past...

Strathprints makes available scholarly Open Access content by researchers in the Centre for the Social History of Health & Healthcare (CSHHH), based within the School of Humanities, and considered Scotland's leading centre for the history of health and medicine.

Research at CSHHH explores the modern world since 1800 in locations as diverse as the UK, Asia, Africa, North America, and Europe. Areas of specialism include contraception and sexuality; family health and medical services; occupational health and medicine; disability; the history of psychiatry; conflict and warfare; and, drugs, pharmaceuticals and intoxicants.

Explore the Open Access research of the Centre for the Social History of Health and Healthcare. Or explore all of Strathclyde's Open Access research...

Image: Heart of England NHS Foundation Trust. Wellcome Collection - CC-BY.

Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors

Cooper, Ian R. and McCarroll, Andrew J. and McGarry, David and Kirkham, James and Pichowicz, Mark and Walker, Rolf and Warrilow, Catherine and Salisbury, Anne-Marie and Savage, Victoria J. and Moyo, Emmanuel and Forward, Henry and Cheung, Jonathan and Metzger, Richard and Gault, Zoe and Nelson, Gary and Hughes, Diarmaid and Cao, Sha and Maclean, John and Charrier, Cédric and Craighead, Mark and Best, Stuart and Stokes, Neil R. and Ratcliffe, Andrew J. (2016) Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors. Bioorganic and Medicinal Chemistry Letters, 26 (17). pp. 4179-83. ISSN 0960-894X

Text (Cooper-etal-BMCL2016-ovel-isothiazolone-class-of-bacterial-type-II-topoisomerase-inhibitors)
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (608kB) | Preview


There is an urgent and unmet medical need for new antibacterial drugs that tackle infections caused by multidrug-resistant (MDR) pathogens. During the course of our wider efforts to discover and exploit novel mechanism of action antibacterials, we have identified a novel series of isothiazolone based inhibitors of bacterial type II topoisomerase. Compounds from the class displayed excellent activity against both Gram-positive and Gram-negative bacteria with encouraging activity against a panel of MDR clinical Escherichia coli isolates when compared to ciprofloxacin. Representative compounds also displayed a promising in vitro safety profile.